Related Experiment Video
Updated: Apr 27, 2026

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
Calcimimetics and outcomes in CKD
1Inserm Unit 1088, UFR de Médecine/Pharmacie, Picardy University Jules Verne , Amiens, France.
Abstract:
In the past decade, several experimental studies demonstrated an inhibitory effect of calcimimetics on the progression of vascular calcification in animals with chronic kidney disease (CKD), in keeping with the expression of the calcium-sensing receptor (CaR) in vascular tissue. In addition, calcimimetics were also found to prevent the arterial remodeling caused by CKD and to slow the progression of atherosclerosis in uremic rats and mice, respectively. The mode of action of these CaR modulators could be both via a better control of secondary hyperparathyroidism and direct effects on the vessel wall. Two main clinical trials, ADVANCE and EVOLVE, recently evaluated in patients with CKD stage 5D the effects of the calcimimetic cinacalcet on the progression of vascular calcification and hard cardiovascular outcomes, respectively. Both trials missed their respective primary end point by intent-to-treat analysis although by other prespecified analyses, including adjustment for baseline characteristics, there was strong suggestive evidence in favor of reductions in risk, in agreement with numerous experimental studies. Further clinical trials are needed to settle this issue definitively.
Insights
Calcimimetics show promise in inhibiting vascular calcification and arterial remodeling in chronic kidney disease (CKD) models. Clinical trials suggest potential cardiovascular benefits, warranting further investigation.
Area of Science:
- Nephrology and Cardiovascular Medicine
- Pharmacology
Background:
- Experimental studies indicate calcimimetics inhibit vascular calcification and arterial remodeling in chronic kidney disease (CKD) models.
- The calcium-sensing receptor (CaR) is expressed in vascular tissue, suggesting a direct role for calcimimetics beyond secondary hyperparathyroidism control.
Approach:
- Review of experimental data and clinical trials (ADVANCE, EVOLVE) evaluating calcimimetics in CKD patients.
- Analysis of cinacalcet's effects on vascular calcification and cardiovascular outcomes in CKD stage 5D.
Key Points:
- Calcimimetics demonstrated inhibitory effects on vascular calcification and arterial remodeling in animal models of CKD.
- Clinical trials ADVANCE and EVOLVE did not meet primary endpoints by intent-to-treat analysis.
- Prespecified analyses in clinical trials suggested potential cardiovascular risk reduction, aligning with experimental findings.
Conclusions:
- While primary endpoints were missed, experimental and secondary analyses suggest calcimimetics may offer cardiovascular benefits in CKD patients.
- Further clinical trials are necessary to definitively establish the role of calcimimetics in managing cardiovascular complications in CKD.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease IV: Nursing Management
Acute Kidney Injury V: Interprofessional Care
Chronic Kidney Disease I: Introduction
Urinary Tract Calculi III: Medical Management

